Skip to main content

Research Repository

Advanced Search

Development of a core outcome set to use in the research and assessment of malignant bowel obstruction: protocol for the RAMBO study (2020)
Journal Article
Currow, D. C., Currow, D. C., Murtagh, F. E., Oliver, A., Baddeley, E., Bravington, A., …Boland, J. (2020). Development of a core outcome set to use in the research and assessment of malignant bowel obstruction: protocol for the RAMBO study. BMJ open, 10(6), https://doi.org/10.1136/bmjopen-2020-039154

INTRODUCTION: Studies regarding the management of malignant bowel obstruction (MBO) report conflicting findings. This is partly due to different outcome measures being used to evaluate severity of MBO and the response to treatments. Furthermore, curr... Read More about Development of a core outcome set to use in the research and assessment of malignant bowel obstruction: protocol for the RAMBO study.

Quality of life changes with duration of chronic breathlessness: a random sample of community-dwelling people. (2020)
Journal Article
Currow, D. C., Chang, S., Grande, E. D., Ferreira, D. H., Kochovska, S., Kinchin PhD, I., …Ekstrom, M. (2020). Quality of life changes with duration of chronic breathlessness: a random sample of community-dwelling people. Journal of pain and symptom management, https://doi.org/10.1016/j.jpainsymman.2020.05.015

Introduction Chronic breathlessness is associated with poorer quality of life. This population study aimed to define dimensions of quality of life (QoL), and duration and dominant causes of breathlessness that most diminished QoL. Methods This... Read More about Quality of life changes with duration of chronic breathlessness: a random sample of community-dwelling people..

A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment (2018)
Journal Article
Hardy, J., Skerman, H., Glare, P., Philip, J., Hudson, P., Mitchell, G., …Yates, P. (2018). A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment. BMC Cancer, 18(1), https://doi.org/10.1186/s12885-018-4404-8

© 2018 The Author(s). Background: Nausea/vomiting (N/V) not related to anti-cancer treatment is common in patients with advanced cancer. The standard approach to management is to define a dominant cause, and treat with an antiemetic selected through... Read More about A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment.

Pharmacovigilance in hospice/palliative care: Net effect of haloperidol for nausea or vomiting (2017)
Journal Article
Digges, M., Hussein, A., Wilcock, A., Crawford, G. B., Boland, J. W., Agar, M. R., …Johnson, M. J. (2018). Pharmacovigilance in hospice/palliative care: Net effect of haloperidol for nausea or vomiting. Journal of palliative medicine, 21(1), 37-43. https://doi.org/10.1089/jpm.2017.0159

Background Haloperidol is widely prescribed as an anti-emetic in patients receiving palliative care, but there is limited evidence to support and refine its use. Objective To explore the immediate and short-term net clinical effects of haloperidol wh... Read More about Pharmacovigilance in hospice/palliative care: Net effect of haloperidol for nausea or vomiting.

Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction (2014)
Journal Article
Currow, D. C., Quinn, S., Agar, M., Fazekas, B., Hardy, J., McCaffrey, N., …Clark, K. (2015). Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction. Journal of pain and symptom management, 49(5), 814-821. https://doi.org/10.1016/j.jpainsymman.2014.09.013

Context Does octreotide reduce vomiting in cancer-associated bowel obstruction? Objectives To evaluate the net effect of adding octreotide or placebo to standardized therapies on the number of days free of vomiting for populations presenting with vom... Read More about Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction.